drugset / Trial / NCT06184334
Management of OAB in Female Patients .
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded prospective randomized placebo-controlled trial.
Timeline
- Start
- 2022-09-14
- Primary completion
- 2022-12-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mirabegron | Other / unclassified | — | Oral |
| Comparator | Solfenacin | Unknown | — | Oral |
| Comparator | Tadalafil | Small molecule | 5 mg | Oral |